CY1117854T1 - Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση - Google Patents

Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση

Info

Publication number
CY1117854T1
CY1117854T1 CY20161100721T CY161100721T CY1117854T1 CY 1117854 T1 CY1117854 T1 CY 1117854T1 CY 20161100721 T CY20161100721 T CY 20161100721T CY 161100721 T CY161100721 T CY 161100721T CY 1117854 T1 CY1117854 T1 CY 1117854T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical form
ophthalmic use
peptide pharmaceutical
local ophthalmic
local
Prior art date
Application number
CY20161100721T
Other languages
English (en)
Inventor
Canonge Rafael Simó
Pascual Cristina Hernández
Carneado Jimena Fernández
Caminals Marc Gómez
I Lluch Ribera Jordana
Sinfreu Josep Farrera
Obiols Berta Ponsati
Original Assignee
Bcn Peptides S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117854(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides S.A. filed Critical Bcn Peptides S.A.
Publication of CY1117854T1 publication Critical patent/CY1117854T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Φαρμακοτεχνική μορφή με πεπτίδια για τοπική οφθαλμική χρήση και η χρησιμοποίηση τους στη θεραπεία και/ή στην τοπική πρόληψη οφθαλμικών νόσων και κατά προτίμηση νόσων του οπισθίου τμήματος του οφθαλμού.
CY20161100721T 2009-12-22 2016-07-22 Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση CY1117854T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931242A ES2362604B1 (es) 2009-12-22 2009-12-22 Formulación tópica oftálmica de péptidos.
PCT/EP2010/007737 WO2011076368A2 (en) 2009-12-22 2010-12-17 Topical ophthalmic peptide formulation

Publications (1)

Publication Number Publication Date
CY1117854T1 true CY1117854T1 (el) 2017-05-17

Family

ID=43928893

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100721T CY1117854T1 (el) 2009-12-22 2016-07-22 Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση

Country Status (34)

Country Link
US (1) US9216208B2 (el)
EP (1) EP2515870B1 (el)
JP (1) JP5920928B2 (el)
KR (1) KR101657737B1 (el)
CN (1) CN102753153B (el)
AR (1) AR079683A1 (el)
AU (1) AU2010335595B2 (el)
BR (1) BR112012015386B8 (el)
CA (1) CA2785104C (el)
CL (1) CL2012001737A1 (el)
CO (1) CO6592047A2 (el)
CY (1) CY1117854T1 (el)
DK (1) DK2515870T3 (el)
ES (2) ES2362604B1 (el)
HK (1) HK1178049A1 (el)
HR (1) HRP20160954T1 (el)
HU (1) HUE028193T2 (el)
IL (1) IL220584A (el)
LT (1) LT2515870T (el)
MX (1) MX338323B (el)
MY (1) MY178169A (el)
NZ (1) NZ600627A (el)
PL (1) PL2515870T3 (el)
PT (1) PT2515870T (el)
RS (1) RS54953B1 (el)
RU (1) RU2561585C2 (el)
SG (1) SG181727A1 (el)
SI (1) SI2515870T1 (el)
SM (1) SMT201600277B (el)
TW (1) TWI548416B (el)
UA (1) UA108484C2 (el)
UY (1) UY33153A (el)
WO (1) WO2011076368A2 (el)
ZA (1) ZA201204522B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6368722B2 (ja) 2013-03-01 2018-08-01 フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
KR102679493B1 (ko) 2017-01-31 2024-07-01 킴벌리-클라크 월드와이드, 인크. 벤조산 에스테르를 포함하는 항균 조성물 및 이를 이용한 세균 생장 억제 방법
US20180325993A1 (en) 2017-05-15 2018-11-15 Sun Pharmaceutical Industries Limited Octreotide injection
TW202133845A (zh) * 2019-11-21 2021-09-16 韓商三進製藥股份有限公司 用於預防或治療眼部疾病之眼用組合物
KR20230133595A (ko) * 2022-03-11 2023-09-19 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
EP0966271A1 (en) * 1997-11-06 1999-12-29 Orbon Corporation Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
CA2263042A1 (en) * 1999-02-25 2000-08-25 Robert W.A. Kuijpers Treatment of edema
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
WO2002009739A1 (en) * 2000-07-27 2002-02-07 Novartis Ag Treatment of ocular disorders with somatostatin analogues
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2005009356A2 (en) 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US20070082841A1 (en) * 2005-09-27 2007-04-12 Aciont, Inc. Ocular administration of immunosuppressive agents
RU2010114034A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Терапевтическое применение нейропептида ei и acth 7-38 и их комбинаций
EP2052716B1 (en) 2007-10-24 2014-12-31 Camurus AB Controlled release formulations

Also Published As

Publication number Publication date
KR101657737B1 (ko) 2016-09-19
DK2515870T3 (en) 2016-09-05
PT2515870T (pt) 2016-08-29
MX2012007282A (es) 2012-10-15
NZ600627A (en) 2014-08-29
MY178169A (en) 2020-10-06
AU2010335595A1 (en) 2012-07-12
JP5920928B2 (ja) 2016-05-18
CN102753153A (zh) 2012-10-24
BR112012015386B1 (pt) 2021-02-23
UY33153A (es) 2011-06-30
JP2013515687A (ja) 2013-05-09
CA2785104C (en) 2016-11-01
ZA201204522B (en) 2013-09-25
ES2587828T3 (es) 2016-10-27
HRP20160954T1 (hr) 2016-10-07
PL2515870T3 (pl) 2016-11-30
TW201141514A (en) 2011-12-01
CN102753153B (zh) 2015-11-25
WO2011076368A3 (en) 2012-03-15
CA2785104A1 (en) 2011-06-30
RU2561585C2 (ru) 2015-08-27
EP2515870A2 (en) 2012-10-31
CO6592047A2 (es) 2013-01-02
AR079683A1 (es) 2012-02-15
US20130210728A1 (en) 2013-08-15
EP2515870B1 (en) 2016-05-25
TWI548416B (zh) 2016-09-11
US9216208B2 (en) 2015-12-22
SMT201600277B (it) 2016-11-10
HK1178049A1 (zh) 2013-09-06
WO2011076368A2 (en) 2011-06-30
CL2012001737A1 (es) 2012-11-16
SG181727A1 (en) 2012-07-30
KR20120120255A (ko) 2012-11-01
RS54953B1 (sr) 2016-11-30
IL220584A (en) 2016-10-31
IL220584A0 (en) 2012-08-30
BR112012015386B8 (pt) 2021-05-25
BR112012015386A2 (pt) 2018-07-24
MX338323B (es) 2016-04-12
SI2515870T1 (sl) 2016-09-30
LT2515870T (lt) 2016-10-10
AU2010335595B2 (en) 2015-08-27
HUE028193T2 (en) 2016-12-28
ES2362604A1 (es) 2011-07-08
UA108484C2 (en) 2015-05-12
RU2012126028A (ru) 2014-01-27
ES2362604B1 (es) 2012-06-28

Similar Documents

Publication Publication Date Title
CY1117854T1 (el) Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1120885T1 (el) Παραγωγα πυρρολο[3,2-d]πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
CY1120429T1 (el) Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
CY1120879T1 (el) Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
IN2015DN04147A (el)
CY1117582T1 (el) Χρηση μιμοτοπων των α-συνουκλεϊνης επιτοπων για θεραπεια ασθενειων σωματος lewy
BR112012011332A2 (pt) agentes direcionados para gadd45beta
BR112016006564A2 (pt) proteínas de ligação desmogleína 2 (dsg2) e usos das mesmas
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
CY1120642T1 (el) Φαρμακευτικη συνθεση της ιβουπροφαιμνης και της τραμαδολης για οφθαλμολογικη χρηση
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
GT200600277A (es) Derivados de prostaglandina
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
BR112018012749A2 (pt) composições para higiene pessoal
BR112014000795A2 (pt) uso cosmético e/ou dermatológico de compostos oligossacarídeos na prevenção e no tratamento de estrias
UY33663A (es) Derivados amínicos para el tratamiento de trastornos proliferativos de la piel
CY1124077T1 (el) Xitozanh aniontikoy φορτιου